Palatin Technologies, Inc. (PTN) News
Filter PTN News Items
PTN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PTN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PTN News From Around the Web
Below are the latest news stories about PALATIN TECHNOLOGIES INC that investors may wish to consider to help them evaluate PTN as an investment opportunity.
Palatin reports positive Phase 2b results in diabetic nephropathyPalatin (PTN) announced topline data for the BREAKOUT study, a Phase IIb study of bremelanotide in diabetic kidney disease. The study showed that bremelanotide therapy for six months, in patients with established Type II diabetic nephropathy, resulted in positive and beneficial results for the majority of patients related to worsening kidney function and disease progression. Clinically meaningful endpoints included: 71% of patients achieved a greater than 30% reduction in the urine protein to cr |
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic NephropathyPalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced topline data for the BREAKOUT study. The BREAKOUT study is a Phase IIb, Multicenter, Open-Label, Prospective Study of BREmelanotide in DiAbetic Kidney Disease to Assess the Efficacy in Reducing Urinary PrOtein and Maintaining Podocyte Density and FUncTion. |
Palatin Technologies Signs Inducement Agreement for Gross Proceeds of $3.4 Million for Investor's Excercise of WarrantsPalatin Technologies (PTN) said Monday it has signed a warrant exercise inducement agreement with an |
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross ProceedsPalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a warrant exercise inducement agreement (the "inducement agreement") with an institutional investor to exercise certain outstanding warrants that the Company issued in June 2024 and October 2023 totaling 3,907,679 shares of the Compan |
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative ColitisPalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the completion of enrollment in its Phase 2 Study of PL8177, a potent melanocortin-1 receptor (MC1R) agonist, in ulcerative colitis (UC). The study is evaluating the safety, tolerability, efficacy, pharmacokinetics, and biomarkers of orally administered PL8177 in adult patients with acti |
Q1 2025 Palatin Technologies Inc Earnings CallQ1 2025 Palatin Technologies Inc Earnings Call |
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ...Palatin Technologies Inc (PTN) navigates a transformative quarter with a focus on obesity programs and strategic partnerships despite a significant revenue drop. |
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial ResultsPalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced operating and financial results for its fiscal first quarter ended September 30, 2024. |
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2025 operating results on Thursday, November 14, 2024, before the open of the U.S. financial markets. |
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced that preclinical data from the Company's melanocortin 4 receptor (MC4R) selective PL7737 obesity program will be highlighted in a poster presentation at ObesityWeek® 2024, the annual meeting of the Obesity Society held in San Antonio, Texas. PL7737 is a highly selective, orally act |